Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Research And Development Expense of $0.00 for the year ending 2024.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -100.0% in Research And Development Expense from 2023 to 2024.
- This data is from ACRO BIOMEDICAL CO., LTD.'s annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.00 | Q3 2020: $0.00 | Q2 2021: $641.7 thousand | Q3 2021: $2.12 million | Q1 2022: $2.52 million | Q2 2022: $2.52 million | Q3 2022: $2.52 million | Q1 2023: $2.52 million | Q2 2023: $1.88 million | Q3 2023: $396.6 thousand | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00.
- Over the full 4 years of available data (2021 to 2024), ACRO BIOMEDICAL CO., LTD.'s Research And Development Expense has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $4.79 million | Fiscal year 2022: $10.08 million | Fiscal year 2021: $5.29 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: